The Efficacy of Bacillus Calmette-Guérin Vaccination of Newborns and Infants in the Prevention of Tuberculosis: Meta-Analyses of the Published Literature
1 Technology Assessment Group, Harvard School of Public Health, Boston, Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston
2 Technology Assessment Group, Harvard School of Public Health, Boston
3 Infectious Disease Unit, Massachusetts General Hospital, Boston
4 Infectious Disease Unit, Mount Auburn Hospital, Cambridge
Technology Assessment Group, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115
Objective. To quantify the efficacy of vaccination of infants with bacillus Calmette-Guérin (BCG) against tuberculosis.
Data sources. MEDLINE with index terms BCG vaccine, tuberculosis, and human; lists of all known studies provided by experts at the Centers for Disease Control and Prevention, the World Health Organization, and other organizations.
Study selection. A total of 1264 articles and abstracts were reviewed for details on BCG vaccination, the availability of concurrent vaccinated and unvaccinated groups, and a tuberculosis outcome. Seventy articles were reviewed in depth for method of vaccine allocation used to create comparable groups, age at vaccination of study participants, comparability of surveillance and follow-up of recipient and concurrent control groups in trials, an appropriately defined control group in case-control studies, and outcome measures (tuberculosis cases and/or deaths). Five prospective trials and eleven case-control studies of vaccination during infancy were included in the present analyses.
Data extraction. We recorded study design, age range of study population, number of patients enrolled, efficacy of vaccine, location of the study, and a series of items to assess the potential for bias in study design, follow-up, and diagnosis. We extracted or computed vaccine efficacy by years since vaccination wherever possible. At least two readers independently extracted data and evaluated data validity.
Data synthesis. The relative risk (RR) or odds ratio (OR) for tuberculosis in vaccinated versus unvaccinated infants was the measure of vaccine efficacy analyzed. A random-effects method estimated a weighted average RR or OR from data extracted from the trials and case-control studies. The protective effect was then computed by 1 - RR or 1 - OR. Overall, the protective effect of vaccination against cases of tuberculosis was 0.74 (95% confidence interval [95% CI], 0.62 to 0.83) when estimated from four randomized controlled trials, and 0.52 (95% CI, 0.38 to 0.64) when estimated from nine case-control studies. Five trials reporting deaths from tuberculosis showed a BCG protective effect of 0.65 (95% CI, 0.12 to 0.86), five studies reporting on meningitis showed a protective effect of 0.64 (95% CI, 0.30 to 0.82), and three studies of disseminated tuberculosis showed a protective effect of 0.78 (95% CI, 0.58 to 0.88). Three case-control studies included separate results for laboratory-confirmed cases of tuberculosis. These studies documented a protective effect of 0.83 (95% CI, 0.58 to 0.93). In a random-effects regression model of the nine case-control studies, study validity score explained 15% of the heterogeneity among study-estimated protective effects, suggesting that better studies reported greater efficacy. Three trials and six case-control studies provided some age-specific information that allowed us to examine the duration of BCG efficacy. Most of this evidence suggested that BCG efficacy may persist through 10 years after infant vaccination.
Conclusion. BCG vaccination of newborns and infants significantly reduces the risk of tuberculosis—by over 50%, on average. Protection has been observed across many populations, study designs, and forms of tuberculosis. Rates of protection against cases that are confirmed by laboratory tests, reflecting reduced error in disease classification and consequently more accurate estimates of BCG efficacy, are highest at 83%.
Submitted on May 31, 1994Accepted on September 14, 1994
This article has been cited by other articles:
 |
|
 |
|
  M. S. Rezai, G. Khotaei, S. Mamishi, M. Kheirkhah, and N. Parvaneh Disseminated Bacillus Calmette-Guerin Infection after BCG Vaccination J Trop Pediatr, December 1, 2008; 54(6): 413 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. C. Miles, M. van der Sande, S. Crozier, O. Ojuola, M. S. Palmero, M. Sanneh, E. S. Touray, S. Rowland-Jones, H. Whittle, M. Ota, et al. Effects of Antenatal and Postnatal Environments on CD4 T-Cell Responses to Mycobacterium bovis BCG in Healthy Infants in The Gambia Clin. Vaccine Immunol., June 1, 2008; 15(6): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Rock, M. Olin, C. A. Baker, T. W. Molitor, and P. K. Peterson Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects Clin. Microbiol. Rev., April 1, 2008; 21(2): 243 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Soares, T. J. Scriba, S. Joseph, R. Harbacheuski, R. A. Murray, S. J. Gelderbloem, A. Hawkridge, G. D. Hussey, H. Maecker, G. Kaplan, et al. Bacillus Calmette-Guerin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles J. Immunol., March 1, 2008; 180(5): 3569 - 3577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Hebert, S. Talarico, D. Yang, R. Durmaz, C. F. Marrs, L. Zhang, B. Foxman, and Z. Yang DNA Polymorphisms in the pepA and PPE18 Genes among Clinical Strains of Mycobacterium tuberculosis: Implications for Vaccine Efficacy Infect. Immun., December 1, 2007; 75(12): 5798 - 5805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Sterling, T. Martire, A. S. de Almeida, L. Ding, D. E. Greenberg, L. A. Moreira, H. Elloumi, A. P.V. Torres, C. C. Sant'Anna, E. Calazans, et al. Immune Function in Young Children With Previous Pulmonary or Miliary/Meningeal Tuberculosis and Impact of BCG Vaccination Pediatrics, October 1, 2007; 120(4): e912 - e921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wu, C. Huang, L. Garcia, A. P. de Leon, J. S. Osornio, M. Bobadilla-del-Valle, L. Ferreira, S. Canizales, P. Small, M. Kato-Maeda, et al. Unique Gene Expression Profiles in Infants Vaccinated with Different Strains of Mycobacterium bovis Bacille Calmette-Guerin Infect. Immun., July 1, 2007; 75(7): 3658 - 3664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Brosch, S. V. Gordon, T. Garnier, K. Eiglmeier, W. Frigui, P. Valenti, S. Dos Santos, S. Duthoy, C. Lacroix, C. Garcia-Pelayo, et al. Genome plasticity of BCG and impact on vaccine efficacy PNAS, March 27, 2007; 104(13): 5596 - 5601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dietrich, R. Billeskov, T. M. Doherty, and P. Andersen Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection J. Immunol., March 15, 2007; 178(6): 3721 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Doi, H. Yamada, T. Yajima, W. Wajjwalku, T. Hara, and Y. Yoshikai H2-M3-Restricted CD8+ T Cells Induced by Peptide-Pulsed Dendritic Cells Confer Protection against Mycobacterium tuberculosis J. Immunol., March 15, 2007; 178(6): 3806 - 3813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Andersen, J. Dietrich, E. M. Agger, N. Y. Lycke, K. Lovgren, and P. Andersen The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis Infect. Immun., January 1, 2007; 75(1): 408 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Walker, G Selby, and I Wacogne Does neonatal BCG vaccination protect against tuberculous meningitis? Arch. Dis. Child., September 1, 2006; 91(9): 789 - 791. [Full Text] [PDF]
|
|
|
|
|
|
S S S Teo and D V Shingadia Does BCG have a role in tuberculosis control and prevention in the United Kingdom? Arch. Dis. Child., June 1, 2006; 91(6): 529 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Castillo-Rodal, M. Castanon-Arreola, R. Hernandez-Pando, J. J. Calva, E. Sada-Diaz, and Y. Lopez-Vidal Mycobacterium bovis BCG Substrains Confer Different Levels of Protection against Mycobacterium tuberculosis Infection in a BALB/c Model of Progressive Pulmonary Tuberculosis Infect. Immun., March 1, 2006; 74(3): 1718 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Srinivasan, L Menon, P Stevens, I Campbell, and M Alfaham Ethnic differences in selective neonatal BCG immunisation: white British children miss out Thorax, March 1, 2006; 61(3): 247 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Rajshekhar BCG vaccination and severity of childhood tuberculous meningitis J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1470 - 1470. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Doherty and P. Andersen Vaccines for Tuberculosis: Novel Concepts and Recent Progress Clin. Microbiol. Rev., October 1, 2005; 18(4): 687 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Skinner, D. N. Wedlock, G. W. de Lisle, M. M. Cooke, R. E. Tascon, J. C. Ferraz, D. B. Lowrie, H. M. Vordermeier, R. G. Hewinson, and B. M. Buddle The Order of Prime-Boost Vaccination of Neonatal Calves with Mycobacterium bovis BCG and a DNA Vaccine Encoding Mycobacterial Proteins Hsp65, Hsp70, and Apa Is Not Critical for Enhancing Protection against Bovine Tuberculosis Infect. Immun., July 1, 2005; 73(7): 4441 - 4444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Roth, P. Gustafson, A. Nhaga, Q. Djana, A. Poulsen, M.-L. Garly, H. Jensen, M. Sodemann, A. Rodriques, and P. Aaby BCG vaccination scar associated with better childhood survival in Guinea-Bissau Int. J. Epidemiol., June 1, 2005; 34(3): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dietrich, C. Aagaard, R. Leah, A. W. Olsen, A. Stryhn, T. M. Doherty, and P. Andersen Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy J. Immunol., May 15, 2005; 174(10): 6332 - 6339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-H. Hovav, Y. Fishman, and H. Bercovier Gamma Interferon and Monophosphoryl Lipid A-Trehalose Dicorynomycolate Are Efficient Adjuvants for Mycobacterium tuberculosis Multivalent Acellular Vaccine Infect. Immun., January 1, 2005; 73(1): 250 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kampmann, G. N. Tena, S. Mzazi, B. Eley, D. B. Young, and M. Levin Novel Human In Vitro System for Evaluating Antimycobacterial Vaccines Infect. Immun., November 1, 2004; 72(11): 6401 - 6407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Olsen, A. Williams, L. M. Okkels, G. Hatch, and P. Andersen Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model Infect. Immun., October 1, 2004; 72(10): 6148 - 6150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Demissie, M. Abebe, A. Aseffa, G. Rook, H. Fletcher, A. Zumla, K. Weldingh, I. Brock, P. Andersen, and T. M. Doherty Healthy Individuals That Control a Latent Infection with Mycobacterium tuberculosis Express High Levels of Th1 Cytokines and the IL-4 Antagonist IL-4{delta}2 J. Immunol., June 1, 2004; 172(11): 6938 - 6943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Aronson, M. Santosham, G. W. Comstock, R. S. Howard, L. H. Moulton, E. R. Rhoades, and L. H. Harrison Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives: A 60-Year Follow-up Study JAMA, May 5, 2004; 291(17): 2086 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, K. Choi, M. R. Olin, S.-N. Cho, and T. W. Molitor {gamma}{delta} T Cells in Immunity Induced by Mycobacterium bovis Bacillus Calmette-Guerin Vaccination Infect. Immun., March 1, 2004; 72(3): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Holten-Andersen, T. M. Doherty, K. S. Korsholm, and P. Andersen Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines Infect. Immun., March 1, 2004; 72(3): 1608 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vekemans, M. O. C. Ota, J. Sillah, K. Fielding, M. R. Alderson, Y. A. W. Skeiky, W. Dalemans, K. P. W. J. McAdam, C. Lienhardt, and A. Marchant Immune Responses to Mycobacterial Antigens in the Gambian Population: Implications for Vaccines and Immunodiagnostic Test Design Infect. Immun., January 1, 2004; 72(1): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Okkels, I. Brock, F. Follmann, E. M. Agger, S. M. Arend, T. H. M. Ottenhoff, F. Oftung, I. Rosenkrands, and P. Andersen PPE Protein (Rv3873) from DNA Segment RD1 of Mycobacterium tuberculosis: Strong Recognition of Both Specific T-Cell Epitopes and Epitopes Conserved within the PPE Family Infect. Immun., November 1, 2003; 71(11): 6116 - 6123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Buddle, D. N. Wedlock, N. A. Parlane, L. A. L. Corner, G. W. de Lisle, and M. A. Skinner Revaccination of Neonatal Calves with Mycobacterium bovis BCG Reduces the Level of Protection against Bovine Tuberculosis Induced by a Single Vaccination Infect. Immun., November 1, 2003; 71(11): 6411 - 6419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. E. Aldwell, I. G. Tucker, G. W. de Lisle, and B. M. Buddle Oral Delivery of Mycobacterium bovis BCG in a Lipid Formulation Induces Resistance to Pulmonary Tuberculosis in Mice Infect. Immun., January 1, 2003; 71(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jason, L. K. Archibald, O. C. Nwanyanwu, P. N. Kazembe, J. A. Chatt, E. Norton, H. Dobbie, and W. R. Jarvis Clinical and Immune Impact of Mycobacterium bovis BCG Vaccination Scarring Infect. Immun., November 1, 2002; 70(11): 6188 - 6195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B Young and G. R Stewart Tuberculosis vaccines Br. Med. Bull., July 1, 2002; 62(1): 73 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Doherty, A. W. Olsen, L. van Pinxteren, and P. Andersen Oral Vaccination with Subunit Vaccines Protects Animals against Aerosol Infection with Mycobacterium tuberculosis Infect. Immun., June 1, 2002; 70(6): 3111 - 3121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Manabe, C. P. Scott, and W. R. Bishai Naturally Attenuated, Orally Administered Mycobacterium microti as a Tuberculosis Vaccine Is Better than Subcutaneous Mycobacterium bovis BCG Infect. Immun., March 1, 2002; 70(3): 1566 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Brandt, J. Feino Cunha, A. Weinreich Olsen, B. Chilima, P. Hirsch, R. Appelberg, and P. Andersen Failure of the Mycobacterium bovis BCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to Tuberculosis Infect. Immun., February 1, 2002; 70(2): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. C. Ota, J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, M. Sanneh, M. Kidd, M. J. Newport, P. Aaby, H. Whittle, P.-H. Lambert, et al. Influence of Mycobacteriumbovis Bacillus Calmette-Guerin on Antibody and Cytokine Responses to Human Neonatal Vaccination J. Immunol., January 15, 2002; 168(2): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahman, M. Sekimoto, I. Takamatsu, K. Hira, T. Shimbo, K. Toyoshima, and T. Fukui Economic evaluation of universal BCG vaccination of Japanese infants Int. J. Epidemiol., April 1, 2001; 30(2): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Arbelaez, K. E Nelson, and A. Munoz BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection Int. J. Epidemiol., December 1, 2000; 29(6): 1085 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. A. W. Skeiky, M. J. Lodes, J. A. Guderian, R. Mohamath, T. Bement, M. R. Alderson, and S. G. Reed Cloning, Expression, and Immunological Evaluation of Two Putative Secreted Serine Protease Antigens of Mycobacterium tuberculosis Infect. Immun., August 1, 1999; 67(8): 3998 - 4007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Berlin and G. A. Colditz The Role of Meta-analysis in the Regulatory Process for Foods, Drugs, and Devices JAMA, March 3, 1999; 281(9): 830 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Webb, T. S. Vedvick, M. R. Alderson, J. A. Guderian, S. S. Jen, P. J. Ovendale, S. M. Johnson, S. G. Reed, and Y. A. W. Skeiky Molecular Cloning, Expression, and Immunogenicity of MTB12, a Novel Low-Molecular-Weight Antigen Secreted by Mycobacterium tuberculosis Infect. Immun., September 1, 1998; 66(9): 4208 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hoft, R. M. Brown, and S. T. Roodman Bacille Calmette-Guerin Vaccination Enhances Human {gamma}{delta} T Cell Responsiveness to Mycobacteria Suggestive of a Memory-Like Phenotype J. Immunol., July 15, 1998; 161(2): 1045 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. TALA-HEIKKILA, J. E. TUOMINEN, and E. O. J. TALA Bacillus Calmette-Guerin Revaccination Questionable with Low Tuberculosis Incidence Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1324 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Abernathy Tuberculosis: An Update Pediatr. Rev., February 1, 1997; 18(2): 50 - 58. [Full Text] [PDF]
|
|
|
|
 |
|
 BCG VACCINE IN NEWBORNS AND INFANTS: A META-ANALYSIS Journal Watch (General), July 28, 1995; 1995(728): 3 - 3. [Full Text]
|
|
